U.S., Feb. 1 -- ClinicalTrials.gov registry received information related to the study (NCT06803888) titled 'Bariatric Surgery Vs. Semaglutide Vs. Tirzepatide' on Jan. 14.
Brief Summary: The recent introduction of the new generation of anti-obesity medications (AOMs) will change the future of obesity treatment. These highly effective medications, such as high-dose semaglutide and tirzepatide, are hormone analogues that augment the incretin function and exert multiple physiological effects by activating glucagon-like peptide-1 (GLP-1) and/or glucose-dependent insulinotropic polypeptide (GIP) distributed in various organs. These medications provide an average of 15-22% weight reduction in one-year trials, which had not been seen in the past w...